Cadrenal Therapeutics ISIN: US1276362076 Forum: Aktien Thema: Hauptdiskussion

Cadrenal Therapeutics (NASDAQ: CVKD) announced on Dec 11, 2025 the acquisition of VLX-1005 and related 12-LOX assets from Veralox Therapeutics, adding a late-stage, first-in-class small‑molecule 12‑lipoxygenase inhibitor for heparin‑induced thrombocytopenia (HIT). VLX-1005 has U.S. Orphan Drug and Fast Track designations, completed two Phase 1 studies showing favorable tolerability, and interim Phase 2 data reporting reductions in thromboembolic events. The release cites a $40 billion global anticoagulation market and an estimated $1 billion HIT market in the US and EU. Veralox may receive upfront, milestone payments and royalties upon commercialization.

https://finance.yahoo.com/news/cadrenal-therapeutics-enhances-anticoagulation-pipeline-120000238.html